قالب وردپرس درنا توس
Home / Business / Roche reported close purchase to buy gene therapy firm spark for hemophilia treatments

Roche reported close purchase to buy gene therapy firm spark for hemophilia treatments



Roche (RHHBY) is approaching an agreement to acquire the gene therapy player Spark Therapeutics (once) for $ 5 billion that the Swiss drugmaker appears to expand his hemophilia treatments.




X [1

9659003] According to the Wall Street Journal, the deal may be announced Monday or earlier, and the value Spark at $ 5 billion. The journal cited people familiar with the case. The prize will give a big prize to Spark's market value, which was around $ 2 billion on Friday.

The agreement will allow Roche access to Sparks pipeline of gene products, including a Pfizer (PFE) partner therapy for hemophilia B and a wholly-owned hemophilia A treatment. Both gene therapies are currently in phase 3 testing.

Spark also has the first food and drug treatment approved gene therapy, Luxturna. Gene therapy was approved in 2017 to treat a rarely inherited eye disorder that often leads to blindness.

Representatives of Spark and Roche concluded comment on e-mail Saturday to Investor's Business Daily.

Betting On Hemophilia Treatments

Roche is betting great on hemophilia treatments with its substance called Hemlibra. Hemlibra is a hemophilia A treatment. Last month, Roche said Hemlibra generated around $ 154 million in 2018 US sales. Global sales were around $ 224 million.

William Anderson, who heads Roche's pharmaceutical division, marked Hemlibra's strong record on the company's quarterly interview in January. 19659004] "You see mainly that we've almost doubled sales every quarter," he told analysts. "I want to say that early reading is that it is not a type of patient receiving Hemlibra."

Gene therapy companies also invest in this space. BioMarin Pharmaceutical (BMRN) and Spark Work on Hemophilia A Treatments, while UniQure (QURE) develops hemophilia B treatments. Pfizer also collaborates with Spark on a hemophilia B gene therapy.

Last year, an ARK Invest analyst told IBD that she believed hemophilia treatments could be a $ 26 billion opportunity by 2025.

Biotech Takeovers in 2019

Takeovers in the Biotech space have been rampant in 2019. [19659003] Bristol-Myers Squibb (BMY) spends $ 74 billion to buy Celgene (CELG). Eli Lilly (LLY) plans to pay $ 8 billion to Loxo Oncology (LOXO). GlaxoSmithKline (GSK) agreed to buy Tesaro for $ 5.1 billion.

Analysts say large biotech companies can look at small and medium-sized biotechnologies to maintain slowing sales with an infusion of new products. 19659004] YOU MUST LIKE:

Can this biotechnology release the sales team with strong gene therapy?

The fastest growing health care providers all have this in common

Get Free IBD Newsletter: Market Prep | Tech Report | How to invest


Source link